JP2025501473A5 - - Google Patents
Info
- Publication number
- JP2025501473A5 JP2025501473A5 JP2024534426A JP2024534426A JP2025501473A5 JP 2025501473 A5 JP2025501473 A5 JP 2025501473A5 JP 2024534426 A JP2024534426 A JP 2024534426A JP 2024534426 A JP2024534426 A JP 2024534426A JP 2025501473 A5 JP2025501473 A5 JP 2025501473A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cas12b
- engineered
- acid residues
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/136761 | 2021-12-09 | ||
| CN2021136761 | 2021-12-09 | ||
| PCT/CN2022/137920 WO2023104185A1 (en) | 2021-12-09 | 2022-12-09 | Engineered cas12b effector proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501473A JP2025501473A (ja) | 2025-01-22 |
| JP2025501473A5 true JP2025501473A5 (https=) | 2025-12-17 |
Family
ID=86686936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534426A Pending JP2025501473A (ja) | 2021-12-09 | 2022-12-09 | エンジニアリングされたＣａｓ１２ｂエフェクタータンパク質及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250051742A1 (https=) |
| EP (1) | EP4444875A4 (https=) |
| JP (1) | JP2025501473A (https=) |
| CN (2) | CN116254246B (https=) |
| WO (1) | WO2023104185A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067403A1 (zh) * | 2023-09-28 | 2025-04-03 | 上海天泽云泰生物医药有限公司 | 用于治疗血红蛋白疾病的组合物和方法 |
| WO2025076291A1 (en) * | 2023-10-06 | 2025-04-10 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
| WO2025096367A1 (en) * | 2023-11-03 | 2025-05-08 | University Of Florida Research Foundation, Inc. | Thermostable and/or charge-engineered cas12a variants for nucleic acid detection |
| CN120330162A (zh) * | 2023-12-06 | 2025-07-18 | 尧唐(上海)生物科技有限公司 | 一种Cas蛋白、包含其的CRISPR-Cas系统及其应用 |
| CN120796267A (zh) * | 2024-07-05 | 2025-10-17 | 上海天泽云泰生物医药有限公司 | 用于使用CRISPR/Cas系统进行基因编辑的经修饰的gRNA |
| WO2026060637A1 (en) * | 2024-09-20 | 2026-03-26 | Shanghai Vitalgen Biopharma Co., Ltd. | Engineered mrna for gene editing using crispr/cas12b |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019127087A1 (zh) * | 2017-12-27 | 2019-07-04 | 中国科学院动物研究所 | 基因组编辑系统和方法 |
| WO2019178427A1 (en) * | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| US20210292747A1 (en) * | 2018-07-27 | 2021-09-23 | The Regents Of The University Of Colorado, A Body Corporate | Engineered chimeric nucleic acid guided nucleases compositions, methods for making, and systems for gene editing |
| JP2021532815A (ja) * | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新規Ｃａｓ１２ｂ酵素およびシステム |
| WO2020081267A2 (en) * | 2018-10-04 | 2020-04-23 | The Regents Of The University Of Colorado, A Body Corporate | Engineered chimeric nucleic acid guided nuclease constructs and uses thereof |
| MX2022004549A (es) * | 2019-10-17 | 2022-07-21 | Pairwise Plants Services Inc | Variantes de nucleasas cas12a, metodos de fabricacion y uso de las mismas. |
| WO2021178934A1 (en) * | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| CN113308451B (zh) * | 2020-12-07 | 2023-07-25 | 中国科学院动物研究所 | 工程化的Cas效应蛋白及其使用方法 |
| CN115851665B (zh) * | 2021-05-27 | 2025-01-24 | 中国科学院动物研究所 | 工程化的Cas12i核酸酶及其效应蛋白以及用途 |
| EP4349979A4 (en) * | 2021-05-27 | 2024-08-21 | Institute Of Zoology, Chinese Academy Of Sciences | MANIPULATED CAS12I NUCLEASE, EFFECTOR PROTEIN AND USE THEREOF |
-
2022
- 2022-12-09 CN CN202211581644.5A patent/CN116254246B/zh active Active
- 2022-12-09 EP EP22903602.5A patent/EP4444875A4/en active Pending
- 2022-12-09 JP JP2024534426A patent/JP2025501473A/ja active Pending
- 2022-12-09 CN CN202280079229.1A patent/CN118339285A/zh active Pending
- 2022-12-09 US US18/717,976 patent/US20250051742A1/en active Pending
- 2022-12-09 WO PCT/CN2022/137920 patent/WO2023104185A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501473A5 (https=) | ||
| JP7761294B2 (ja) | 遺伝子編集における非意図的な変異の阻害 | |
| US20230091847A1 (en) | Compositions and methods for improving homogeneity of dna generated using a crispr/cas9 cleavage system | |
| US20240200044A1 (en) | Evolution of talens | |
| AU2021201257B2 (en) | Cas9 variants and uses thereof | |
| KR102598819B1 (ko) | 서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq) | |
| JP7679311B2 (ja) | プログラム可能塩基エディターシステムを用いた一塩基多型編集法 | |
| JP2025013768A (ja) | プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法 | |
| JP6633524B2 (ja) | 操作された転写活性化因子様エフェクター（ｔａｌｅ）ドメインおよびその使用 | |
| KR20200121782A (ko) | 아데노신 염기 편집제의 용도 | |
| KR20220150329A (ko) | 클래스 ii, 타입 v crispr 시스템 | |
| KR20180069898A (ko) | 핵염기 편집제 및 그의 용도 | |
| US20220389418A1 (en) | Rna-guided cas nucleases and uses thereof in diagnostics and therapy | |
| CA3170318A1 (en) | Phi29 mutants and use thereof | |
| CN114144519A (zh) | 单碱基置换蛋白以及包含其的组合物 | |
| WO2023196476A1 (en) | Compositions and methods of prime editor guide rna/sequencing tag complexes | |
| Yin et al. | Advances in the engineering of the gene editing enzymes and the genomes: understanding and handling the off-target effects of CRISPR/Cas9 | |
| Rousseau et al. | Transposition of IS 911 | |
| WO2025139809A1 (zh) | Cas蛋白、组合蛋白、核酸分子、核糖核蛋白复合物、重组载体、转基因细胞及其应用 | |
| WO2024173573A1 (en) | Crispr-transposon systems and components | |
| US20240287547A1 (en) | Genetic modification | |
| JP2025505212A (ja) | プライム編集システムを用いたゲノム編集のプロセスで起こり得るオフターゲットを予測するための方法 | |
| EP4450634A1 (en) | Method for detecting integration site | |
| CN111690724B (zh) | 一种检测双链断裂产生试剂活性的方法 | |
| WO2024235991A1 (en) | Rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases |